CRISPR-Cas9 genome editing of immune cell types holds great therapeutic potential, but application of genome editing to primary human immune cells has been hampered by challenges in efficient delivery and expression of the CRISPR machinery. Explore our protocols and resources for information on how to overcome these barriers and perform high-efficiency genome editing of these difficult-to-manipulate cell types in your own lab.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
your email preferences at any time.